The Pancreatic Adenocarcinoma Gene Environment Risk Study -A Prospective Cohort Study of Patients at Risk or Having Pancreatic Disease
After informed consent, demographic and epidemiological data will be collected from the
PAGER questionnaires. Blood and urine for DNA and biomarkers will be obtained from at least
1000 individuals with pancreatic cancer, 1000 high-risk subjects, 500 spouse (environment)
controls and 500 population controls. Samples will be collected using EDRN SOPS, split into
multiple storage vials, and stored at -80° C. The samples will then be used for experiments
to address the specific aims of this study.
Observational Model: Case Control, Time Perspective: Prospective
The data will be used in cohort association studies. Endpoints will depend on the number of patients in the study and the number of markers that are being evaluated.
Randall Brand, MD
University of Pittsburgh
United States: Institutional Review Board
|UPMC Hillman Cancer Center||Pittsburgh, Pennsylvania 15232|
|UPMC Presbyterian Hospital||Pittsburgh, Pennsylvania 15213|
|UPMC Shadyside Hospital||Pittsburgh, Pennsylvania 15232|